Table 1 Patient characteristics.
CLL-HRS | CLL-HL | Total | |
|---|---|---|---|
N | 15 | 31 | 46 |
Median [range] age at CLL diagnosis | 65 [44–93] | 63 [42–82] | 63 [42–93] |
Median [range] age at CLL-HRS/CLL-HL diagnosis | 72 [47–93] | 71 [52–89] | 72 [47–93] |
Sex, males | 13 (87%) | 22 (71%) | 35 (76%) |
Median [range] time from CLL diagnosis, years | 4.9 [0–34.5] | 6.6 [0–24.5] | 6.2 [0–34.5] |
Characteristics at the time of diagnosis of CLL | |||
Median [range] Beta-2 microglobulin | 2.4 [1.8–7.4] | 4.0 [1.9-8.3] | 2.9 [1.8-8.3] |
Missing | 6 | 21 | 27 |
Rai Stage | |||
0 | 4 (33%) | 10 (40%) | 14 (38%) |
I–II | 7 (58%) | 15 (60%) | 22 (59%) |
III–IV | 1 (8%) | 0 (0%) | 1 (3%) |
Missing | 3 | 6 | 9 |
Unmutated IGHV genes | 8 (89%) | 7 (70%) | 15 (79%) |
Missing | 6 | 21 | 27 |
FISH | |||
17delp | 0 (0%) | 2 (14%) | 2 (9%) |
11delq | 4 (44%) | 3 (21%) | 7 (30%) |
Trisomy 12 | 3 (33%) | 4 (29%) | 7 (30%) |
None detected | 1 (11%) | 4 (29%) | 5 (22%) |
13delq | 1 (11%) | 1 (7%) | 2 (9%) |
Missing | 6 | 17 | 23 |
CLL-IPI risk | |||
Low | 1 (14%) | 1 (13%) | 2 (13%) |
Intermediate | 2 (29%) | 2 (25%) | 4 (27%) |
High | 4 (57%) | 3 (38%) | 7 (47%) |
Very High | 0 (0%) | 2 (25%) | 2 (13%) |
Missing | 8 | 23 | 31 |
Characteristics related to diagnosis of CLL-HRS/CLL-HL | |||
Hasenclever Index | |||
0–2 | 2 (20%) | 6 (24%) | 8 (23%) |
3 | 5 (50%) | 3 (12%) | 8 (23%) |
4 | 3 (30%) | 9 (36%) | 12 (34%) |
5–7 | 0 (0%) | 7 (28%) | 7 (20%) |
Missing | 5 | 6 | 11 |
Median [range] number of CLL treatments prior to diagnosis of CLL-HRS and CLL-HL | 0 [0–8] | 1 [0–8] | 1 [0–8] |
Therapy of CLL-HRS and CLL-HL | |||
None | 2 (13%) | 0 (0%) | 2 (4%) |
CLL-directed | 7 (47%) | 2 (7%) | 9 (20%) |
HL-directed | 6 (40%) | 28 (93%) | 34 (76%) |
Missing | 0 | 1 | 1 |
